Showing results (321-330 of 1,873) with videos related to

Sort By:
Pageof 188
Pulmonary Pharmacology & Therapeutics|January 27, 1999
The effect of the ETA receptor antagonist (CI-1020) in rats with established hypoxic pulmonary hypertensionW Sheedy, S Haleen, A H Morice
Pulmonary Pharmacology & Therapeutics|January 27, 1999
Characterization of the enzyme involved in the processing of big endothelin-1 in human lung epithelial cellsJ D Aubert, B Carnal, J Ricou, et al.
Pulmonary Pharmacology & Therapeutics|January 27, 1999
Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in ratsS E Mutsaers, R P Marshall, N R Goldsack, et al.
Pulmonary Pharmacology & Therapeutics|November 7, 2016
Biochemical and functional characterization of glycosaminoglycans released from degranulating rat peritoneal mast cells: Insights into the physiological role of endogenous heparinRebecca Lever, Amir Smailbegovic, Yanira Riffo-Vasquez, et al.
Pulmonary Pharmacology & Therapeutics|November 7, 2016
The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxisLineu Baldissera, Dalize M Squebola-Cola, Marina C Calixto, et al.
Pulmonary Pharmacology & Therapeutics|January 8, 2017
MiR-23b controls TGF-β1 induced airway smooth muscle cell proliferation via direct targeting of Smad3Ming Chen, Jianting Shi, Wei Zhang, et al.
Pulmonary Pharmacology & Therapeutics|May 6, 2014
Facing multi-drug resistant tuberculosisGiovanni Sotgiu, Giovanni Battista Migliori
Pulmonary Pharmacology & Therapeutics|March 29, 2017
Ursolic acid attenuates cigarette smoke-induced emphysema in rats by regulating PERK and Nrf2 pathwaysLi Lin, Yan Yin, Gang Hou, et al.
Pulmonary Pharmacology & Therapeutics|March 26, 2013
Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21Yan Gao, Jia Lu, Yu Zhang, et al.
Pulmonary Pharmacology & Therapeutics|March 26, 2013
Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysisWilliam V La Via, Gerard F Notario, Xiang-Qing Yu, et al.
Pageof 188